Literature DB >> 12364347

Impaired fasting glucose, blood pressure and cardiovascular disease mortality.

Patrick Henry1, Frédérique Thomas, Athanase Benetos, Louis Guize.   

Abstract

Impaired fasting glucose (fasting plasma glucose 6.1 to 6.9 mmol/L [110 to 125 mg/dL]) is a common glycemic disorder which usually progress to diabetes mellitus. The relationships between impaired fasting glucose, other risk factors including blood pressure, and mortality have never been clearly investigated. We studied 63 443 consecutive men (ages 21 to 60 years), each of whom had a routine health examination with a fasting plasma glucose measurement. Men with known ischemic cardiac disease and treatment for diabetes or hypertension were excluded. Impaired fasting glucose was found in 10 773 (17.0%) of these men. Mean body mass index, serum triglyceride and cholesterol levels, and systolic, diastolic, and pulse blood pressure were significantly higher for men with impaired fasting glucose compared with those men with normal fasting glucose (fasting plasma glucose 3.9 to 6.0 mmol/L). When adjusted for confounding variables, relative risk of 8-year cardiovascular mortality associated with impaired fasting glucose was dependent on systolic blood pressure level (1.02 [95% CI: 0.62 to 1.70] when <140 mm Hg and 2.10 [95% CI: 1.16 to 3.80] between 140 and 160 mm Hg). Inversely, relative risk of 8-year cardiovascular mortality associated with moderate systolic hypertension (140 to 159 mm Hg) compared with normal systolic blood pressure (<140 mm Hg) was highly dependent on the glycemic status (2.97 [95% CI: 1.58 to 5.55] for men with impaired fasting glucose compared with 1.35 [95% CI: 0.84 to 2.18] in those with normal fasting glucose). Similar results were found concerning overall mortality. In conclusion, the presence of moderate systolic hypertension can identify subjects with impaired fasting glucose who are at risk of cardiovascular and overall mortality, and vice versa, probably through the metabolic syndrome.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12364347     DOI: 10.1161/01.hyp.0000032853.95690.26

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  32 in total

Review 1.  Metabolic issues in the Antihypertensive and Lipid-Lowering Heart Attack Trial Study.

Authors:  Henry A Punzi; Connie F Punzi
Journal:  Curr Hypertens Rep       Date:  2004-04       Impact factor: 5.369

2.  Association of branched and aromatic amino acids levels with metabolic syndrome and impaired fasting glucose in hypertensive patients.

Authors:  Liming Weng; Eoin Quinlivan; Yan Gong; Amber L Beitelshees; Mohamed H Shahin; Stephen T Turner; Arlene B Chapman; John G Gums; Julie A Johnson; Reginald F Frye; Timothy J Garrett; Rhonda M Cooper-DeHoff
Journal:  Metab Syndr Relat Disord       Date:  2015-02-09       Impact factor: 1.894

3.  Impaired function of coronary BK(Ca) channels in metabolic syndrome.

Authors:  Léna Borbouse; Gregory M Dick; Shinichi Asano; Shawn B Bender; U Deniz Dincer; Gregory A Payne; Zachary P Neeb; Ian N Bratz; Michael Sturek; Johnathan D Tune
Journal:  Am J Physiol Heart Circ Physiol       Date:  2009-09-11       Impact factor: 4.733

Review 4.  Hypertension with diabetes mellitus: significance from an epidemiological perspective for Japanese.

Authors:  Yukako Tatsumi; Takayoshi Ohkubo
Journal:  Hypertens Res       Date:  2017-07-13       Impact factor: 3.872

5.  Metabolic syndrome reduces the contribution of K+ channels to ischemic coronary vasodilation.

Authors:  Léna Borbouse; Gregory M Dick; Gregory A Payne; Zachary C Berwick; Zachary P Neeb; Mouhamad Alloosh; Ian N Bratz; Michael Sturek; Johnathan D Tune
Journal:  Am J Physiol Heart Circ Physiol       Date:  2010-01-29       Impact factor: 4.733

Review 6.  Differential effects of antihypertensive drugs on new-onset diabetes?

Authors:  William J Elliott
Journal:  Curr Hypertens Rep       Date:  2005-08       Impact factor: 5.369

7.  The characteristics of impaired fasting glucose associated with obesity and dyslipidaemia in a Chinese population.

Authors:  Yun Qian; Yudi Lin; Tiemei Zhang; Jianling Bai; Feng Chen; Yi Zhang; Senlin Luo; Hongbing Shen
Journal:  BMC Public Health       Date:  2010-03-17       Impact factor: 3.295

8.  Cardiovascular disease mortality in Europeans in relation to fasting and 2-h plasma glucose levels within a normoglycemic range.

Authors:  Feng Ning; Jaakko Tuomilehto; Kalevi Pyörälä; Altan Onat; Stefan Söderberg; Qing Qiao
Journal:  Diabetes Care       Date:  2010-04-27       Impact factor: 19.112

9.  The joint association of self-rated health and diabetes status on 14-year mortality in elderly men and women.

Authors:  R Dankner; L Olmer; G Kaplan; A Chetrit
Journal:  Qual Life Res       Date:  2016-05-02       Impact factor: 4.147

10.  Location of arterial stiffening differs in those with impaired fasting glucose versus diabetes: implications for left ventricular hypertrophy from the Multi-Ethnic Study of Atherosclerosis.

Authors:  Pairoj Rerkpattanapipat; Ralph B D'Agostino; Kerry M Link; Eyal Shahar; Joao A Lima; David A Bluemke; Shantanu Sinha; David M Herrington; W Gregory Hundley
Journal:  Diabetes       Date:  2009-01-09       Impact factor: 9.461

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.